Dexcel Pharma Technologies Ltd. 4
4 · Intec Pharma Ltd. · Filed Feb 4, 2020
Insider Transaction Report
Form 4
Dexcel Pharma Technologies Ltd.
10% Owner
Transactions
- Sale
Ordinary Shares
2020-01-31$0.31/sh−725,951$224,319→ 4,424,897 total - Sale
Ordinary Shares
2020-02-03$0.32/sh−80,000$25,440→ 4,344,897 total - Sale
Ordinary Shares
2020-02-04$0.29/sh−110,000$31,900→ 4,234,897 total
Footnotes (5)
- [F1]Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over ordinary shares of Intec Pharma Ltd. The Ordinary Shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
- [F2]The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.300 to $0.325, inclusive.
- [F3]The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.300 to $0.324, inclusive.
- [F4]The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.290 to $0.294, inclusive.
- [F5]The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.